🏢 官网IRURGNCodex · 实盘不做把握 9/10
北京时间·🕒 发布 20:00:00·⟳ 抓取 20:03:19 +3m19s·⚡ 决策 07-29 20:22:32 +19m13s·90.0 天前
UroGen宣布将于8月5日披露二季度业绩并召开电话会
本次公告只是业绩披露日期和电话会安排，没有披露收入、利润、指引、临床、监管或商业化新增事实。
📄 原文URGN↗ 原文
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET PRINCETON, N.J. , July 29, 2026 (…
不做 UroGen Pharma（URGN.US）
仅为例行业绩发布时间和电话会安排，没有方向性增量信息；需等8月5日实际财报和电话会内容后再研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-29 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次公告只是业绩披露日期和电话会安排，没有披露收入、利润、指引、临床、监管或商业化新增事实。
主要风险
- 真正可交易信息需等2026年8月5日盘前二季度财报和电话会内容。
原文全文
展开原文 · 1,715 字
Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET
PRINCETON, N.J.
,
July 29, 2026
(GLOBE NEWSWIRE) --
UroGen Pharma Ltd.
(Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2026 financial results on
Wednesday, August 5
th
, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at
10:00 AM Eastern Time
.
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations
website
. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit
www.UroGen.com
to learn more or follow us on X, @UroGenPharma.
INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083
PRINCETON, N.J.
,
July 29, 2026
(GLOBE NEWSWIRE) --
UroGen Pharma Ltd.
(Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2026 financial results on
Wednesday, August 5
th
, 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at
10:00 AM Eastern Time
.
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations
website
. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit
www.UroGen.com
to learn more or follow us on X, @UroGenPharma.
INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。